Towards broadly protective polyvalent vaccines against hand, foot and mouth disease

Microbes and Infection

Volumn 17, Issue 2, 2015, Pages 155-162

  Liu, Qingwei ^a   Tong, Xin ^b   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b Shanghai Zerun Biotechnology CoLtd   (China)

Author keywords

Coxsackievirus A16; Enterovirus 71; Hand, foot, and mouth disease; Polyvalent vaccine

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; PEPTIDE VACCINE; POLYVALENT HAND FOOT AND MOUTH DISEASE VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ARTICLE; COXSACKIE VIRUS INFECTION; DRUG DESIGN; DRUG TARGETING; ENTEROVIRUS INFECTION; HAND FOOT AND MOUTH DISEASE; HEALTH HAZARD; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PRIORITY JOURNAL; ASIA; ENTEROVIRUS A; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; VIROLOGY;

COXSACKIEVIRUS; ENTEROVIRUS; HUMAN ENTEROVIRUS 71;

ASIA; CHILD, PRESCHOOL; ENTEROVIRUS A, HUMAN; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFANT; VIRAL VACCINES;

EID: 84921599753     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.11.004     Document Type: Article

References (70)

1. Repass G.L., Palmer W.C., Stancampiano F.F. Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Cleve Clin J Med 2014, 81:537-543.
2. Zeng M., Pu D.B., Mo X.W., Zhu C.M., Gong S.T., Xu Y., et al. Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study. Emerg Microbes Infect 2013, 2.
3. Abzug M.J. The enteroviruses: problems in need of treatments. J Infect 2014, 68(Suppl. 1):S108-S114.
4. Weng K.F., Chen L.L., Huang P.N., Shih S.R. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010, 12:505-510.
5. Robinson C.R., Doane F.W., Rhodes A.J. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, summer 1957; isolation of group A Coxsackie virus. Can Med Assoc J 1958, 79:615-621.
6. Chua K.B., Kasri A.R. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011, 26:221-228.
7. Huang P.N., Shih S.R. Update on enterovirus 71 infection. Curr Opin Virol 2014, 5:98-104.
8. Bessaud M., Razafindratsimandresy R., Nougairede A., Joffret M.L., Deshpande J.M., Dubot-Peres A., et al. Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One 2014, 9:e90624.
9. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10:778-790.
10. Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2014, 10:360-367.
11. Blomqvist S., Klemola P., Kaijalainen S., Paananen A., Simonen M.L., Vuorinen T., et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol 2010, 48:49-54.
12. Yamayoshi S., Fujii K., Koike S. Receptors for enterovirus 71. Emerg Microbes Infect 2014, 3.
13. Yang F., Zhang T., Hu Y., Wang X., Du J., Li Y., et al. Survey of enterovirus infections from hand, foot and mouth disease outbreak in China, 2009. Virol J 2011, 8:508.
14. Zhang H.M., Li C.R., Liu Y.J., Liu W.L., Fu D., Xu L.M., et al. To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009, 23:334-336.
15. Pan H., Zhu Y.F., Qi X., Zhang Y.J., Li L., Deng F., et al. Analysis on the epidemiological and genetic characteristics of enterovirus type 71 and Coxsackie A16 virus infection in Jiangsu, China. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30:339-343.
16. Yip C.C., Lau S.K., Zhou B., Zhang M.X., Tsoi H.W., Chan K.H., et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol 2010, 155:1413-1424.
17. Zhang Y., Zhu Z., Yang W., Ren J., Tan X., Wang Y., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010, 7:94.
18. Liang Z., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013, 7:111-121.
19. Lu S. EV71 vaccines: a milestone in the history of global vaccine development. Emerg Microbes Infect 2014, 3.
20. Chu S.C., Wang E.T., Liu D.P. Is a monovalent vaccine against enterovirus 71 sufficient? A review of enterovirus 71 vaccine development based on enterovirus surveillance in Taiwan. J Formos Med Assoc 2013, 112:508-509.
21. Lee M.S., Tseng F.C., Wang J.R., Chi C.Y., Chong P., Su I.J. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012, 6:e1737.
22. Wong S.S., Yip C.C., Lau S.K., Yuen K.Y. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 2010, 138:1071-1089.
23. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9:149-156.
24. Xu J., Qian Y., Wang S., Serrano J.M., Li W., Huang Z., et al. EV71: an emerging infectious disease vaccine target in the far east?. Vaccine 2010, 28:3516-3521.
25. Chou A.H., Liu C.C., Chang C.P., Guo M.S., Hsieh S.Y., Yang W.H., et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 2012, 7:e34834.
26. Cheng A., Fung C.P., Liu C.C., Lin Y.T., Tsai H.Y., Chang S.C., et al. A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013, 31:2471-2476.
27. Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013, 8:e79783.
28. Li J.X., Mao Q.Y., Liang Z.L., Ji H., Zhu F.C. Development of enterovirus 71 vaccines: from the lab bench to phase III clinical trials. Expert Rev Vaccines 2014, 13:609-618.
29. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.
30. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
31. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
32. Zhang H., An D., Liu W., Mao Q., Jin J., Xu L., et al. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS One 2014, 9:e100545.
33. Zhao Q., Li S., Yu H., Xia N., Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013, 31:654-663.
34. Hu Y.C., Hsu J.T., Huang J.H., Ho M.S., Ho Y.C. Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells. Biotechnol Lett 2003, 25:919-925.
35. Chung Y.C., Huang J.H., Lai C.W., Sheng H.C., Shih S.R., Ho M.S., et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 2006, 12:921-927.
36. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26:1855-1862.
37. Lin Y.L., Yu C.I., Hu Y.C., Tsai T.J., Kuo Y.C., Chi W.K., et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012, 30:1305-1312.
38. Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 2013, 8:e57601.
39. Chung C.Y., Chen C.Y., Lin S.Y., Chung Y.C., Chiu H.Y., Chi W.K., et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010, 28:6951-6957.
40. Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013, 31:3281-3287.
41. Arita M., Shimizu H., Nagata N., Ami Y., Suzaki Y., Sata T., et al. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J Gen Virol 2005, 86:1391-1401.
42. Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007, 81:9386-9395.
43. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 2007, 125:61-68.
44. Chang G.H., Luo Y.J., Wu X.Y., Si B.Y., Lin L., Zhu Q.Y. Monoclonal antibody induced with inactivated EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 2010, 7:106.
45. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2002, 20:895-904.
46. Chou A.H., Liu C.C., Chang J.Y., Lien S.P., Guo M.S., Tasi H.P., et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin Dev Immunol 2012, 2012:831282.
47. Chiu C.H., Chu C., He C.C., Lin T.Y. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 2006, 8:1671-1678.
48. Yu Z., Huang Z., Sao C., Huang Y., Zhang F., Ma G., et al. Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. Arch Virol 2013, 158:1071-1077.
49. Tung W.S., Bakar S.A., Sekawi Z., Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007, 5:6.
50. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 2011, 29:4362-4372.
51. Foo D.G., Alonso S., Chow V.T., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 2007, 9:1299-1306.
52. Tian X., Su X., Li X., Li H., Li T., Zhou Z., et al. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One 2012, 7:e41381.
53. Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 2014, 88:72-81.
54. Li Y.X., Zhao H., Cao R.Y., Deng Y.Q., Han J.F., Zhu S.Y., et al. Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice. Virol J 2014, 11:79.
55. Sickles G.M., Mutterer M., Feorino P., Plager H. Recently classified types of Coxsackie virus, group A; behavior in tissue culture. Proc Soc Exp Biol Med 1955, 90:529-531.
56. Zhu J., Luo Z., Wang J., Xu Z., Chen H., Fan D., et al. Phylogenetic analysis of enterovirus 71 circulating in Beijing, China from 2007 to 2009. PLoS One 2013, 8:e56318.
57. Xu W., Liu C.F., Yan L., Li J.J., Wang L.J., Qi Y., et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012, 9:8.
58. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013, 31:2215-2221.
59. Qi An W., Guo Su Z., Wen Pan R., Ping Yang B., Chao Zhang Y., Shi L., et al. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother 2014, 10:628-639.
60. Li J., Chang J., Liu X., Yang J., Guo H., Wei W., et al. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol 2014, 95:1083-1093.
61. Yang E., Cheng C., Zhang Y., Wang J., Che Y., Pu J., et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother 2014, 10:1266-1273.
62. Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012, 30:6642-6648.
63. Gong M., Zhu H., Zhou J., Yang C., Feng J., Huang X., et al. Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development. J Virol 2014, 88:6444-6452.
64. Zhao H., Li H.Y., Han J.F., Deng Y.Q., Li Y.X., Zhu S.Y., et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 2013, 97:10445-10452.
65. Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 2013, 31:2130-2136.
66. Li J.L., Yuan J., Yang F., Wu Z.Q., Hu Y.F., Xue Y., et al. Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect 2014, 69:299-303.
67. Puenpa J., Chieochansin T., Linsuwanon P., Korkong S., Thongkomplew S., Vichaiwattana P., et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012. Emerg Infect Dis 2013, 19:641-643.
68. Ku Z., Liu Q., Ye X., Cai Y., Wang X., Shi J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014, 32:4296-4303.
69. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014, 32:2406-2412.
70. Lin C.W., Liu C.C., Lu T.C., Liu S.J., Chow Y.H., Chong P., et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int 2014, 2014:670506.